Newsroom
Explore the latest news and events from Mendus, as well as expert perspectives and patient stories. Here you’ll find company updates, scientific insights, and interviews that highlight the science, unmet medical need, and the people working to change the course of cancer treatment.
Press Releases
Events
Expert Perspectives
Scientific advances are essential to improving patient outcomes. These interviews highlight the latest scientific developments, unmet medical needs, and the future of treatment for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
Prof. Dr. Tariq Mughal
Professor Mughal, Chief Medical and Scientific Officer at Mendus, is a globally recognized expert in myeloid blood cancers, with extensive experience spanning clinical practice, academia and the bio pharmaceutical industry. In this interview, he discusses the current treatment landscape, future treatment strategies, and the potential role of immunotherapy in reducing the risk of relapse and improving long-term outcomes.
Prof. Dr. Bjørn Tore Gjertsen
Professor Gjertsen has studied Mendus’ lead product, vididencel, in AML as part of the ADVANCE II trial. He is also the principal investigator of Mendus’ first clinical trial evaluating vididencel in CML. Here, he shares his perspectives on recent advances in myeloid blood cancers, the challenges of residual disease, and how activation of the immune system may support durable disease control and treatment-free remission (TFR).
Patient Stories
Every cancer journey is unique. These stories provide perspectives on living with myeloid blood cancers – highlighting challenges, hopes, and personal experiences.
Jacob’s AML Story
After enduring two difficult rounds of chemotherapy and a long recovery, Jacob joined the ADVANCE II trial evaluating vididencel in AML. He shares his experience of treatment, resilience, and regaining quality of life after cancer.
Solveig’s CML Story
Diagnosed with CML at 25, Solveig shares her experience of living with a chronic blood cancer and the challenges of long-term treatment. Her story highlights the progress made – and the need for continued innovation.
Giora’s CML Story
When Giora was diagnosed with CML he was told he had only a few years to live. Today, he has been in treatment-free remission for more than a decade. Giora advocates for CML patients, stressing the importance to improve quality of life.